Although the S&P 500 is down 3.2% over the past six months, U.S. Physical Therapy’s stock price has fallen further to $74.73, losing shareholders 12% of their capital. This may have investors wondering how to approach the situation.

Is there a buying opportunity in U.S. Physical Therapy, or does it present a risk to your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free.

Why Is U.S. Physical Therapy Not Exciting?

Even with the cheaper entry price, we're cautious about U.S. Physical Therapy. Here are three reasons you should be careful with USPH and a stock we'd rather own.

1. Fewer Distribution Channels Limit its Ceiling

Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.

With just $781 million in revenue over the past 12 months, U.S. Physical Therapy is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.

2. EPS Barely Growing

Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions.

U.S. Physical Therapy’s EPS grew at an unimpressive 1.9% compounded annual growth rate over the last five years, lower than its 13% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded.

3. Free Cash Flow Margin Dropping

If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.

As you can see below, U.S. Physical Therapy’s margin dropped by 6 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. U.S. Physical Therapy’s free cash flow margin for the trailing 12 months was 7.8%.

Final Judgment

U.S. Physical Therapy’s business quality ultimately falls short of our standards. After the recent drawdown, the stock trades at 25.8× forward P/E (or $74.73 per share). This multiple tells us a lot of good news is priced in - you can find more timely opportunities elsewhere. We’d recommend looking at a dominant Aerospace business that has perfected its M&A strategy.

Stocks We Would Buy Instead of U.S. Physical Therapy

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.